These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 32380429)
1. Systemic treatment of brain metastases in non-small cell lung cancer. Page S; Milner-Watts C; Perna M; Janzic U; Vidal N; Kaudeer N; Ahmed M; McDonald F; Locke I; Minchom A; Bhosle J; Welsh L; O'Brien M Eur J Cancer; 2020 Jun; 132():187-198. PubMed ID: 32380429 [TBL] [Abstract][Full Text] [Related]
2. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000 [TBL] [Abstract][Full Text] [Related]
3. Systemic Therapy for Lung Cancer Brain Metastases. Pellerino A; Bruno F; Rudà R; Soffietti R Curr Treat Options Oncol; 2021 Oct; 22(12):110. PubMed ID: 34693454 [TBL] [Abstract][Full Text] [Related]
4. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review. Khasraw M; Yalamanchili P; Santhanagopal A; Wu C; Salas M; Meng J; Karnoub M; Esker S; Felip E Adv Ther; 2024 May; 41(5):1815-1842. PubMed ID: 38509433 [TBL] [Abstract][Full Text] [Related]
5. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors. Wrona A; Dziadziuszko R; Jassem J Cancer Treat Rev; 2018 Dec; 71():59-67. PubMed ID: 30366200 [TBL] [Abstract][Full Text] [Related]
6. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642 [TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. Metro G; Chiari R; Ricciuti B; Rebonato A; Lupattelli M; Gori S; Bennati C; Castrioto C; Floridi P; Minotti V; Chiarini P; Crinò L Expert Opin Pharmacother; 2015; 16(17):2601-13. PubMed ID: 26439599 [TBL] [Abstract][Full Text] [Related]
8. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378 [TBL] [Abstract][Full Text] [Related]
9. Molecular subtyping of brain metastases and implications for therapy. Renfrow JJ; Lesser GJ Curr Treat Options Oncol; 2013 Dec; 14(4):514-27. PubMed ID: 23907440 [TBL] [Abstract][Full Text] [Related]
10. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436 [TBL] [Abstract][Full Text] [Related]
11. A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer. McGranahan T; Nagpal S Curr Treat Options Oncol; 2017 Apr; 18(4):22. PubMed ID: 28391420 [TBL] [Abstract][Full Text] [Related]
12. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases. Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068 [TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS. Klempner SJ; Ou SH Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806 [TBL] [Abstract][Full Text] [Related]
14. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? Liao BC; Lin CC; Yang JC Expert Opin Pharmacother; 2018 Jun; 19(8):851-864. PubMed ID: 29726292 [TBL] [Abstract][Full Text] [Related]
15. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Toyokawa G; Seto T; Takenoyama M; Ichinose Y Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831 [TBL] [Abstract][Full Text] [Related]
16. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer. Wang W; Sun X; Hui Z Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380 [TBL] [Abstract][Full Text] [Related]
17. Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases. Thomas CM; Lee CS J Oncol Pharm Pract; 2019 Apr; 25(3):623-637. PubMed ID: 30176786 [TBL] [Abstract][Full Text] [Related]
18. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. Cameron L; Solomon B Curr Treat Options Oncol; 2015 Oct; 16(10):49. PubMed ID: 26318457 [TBL] [Abstract][Full Text] [Related]
19. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy. Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785 [TBL] [Abstract][Full Text] [Related]
20. Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis. Muhammet Hacioglu B; Kostek O; Erdogan B; Uzunoglu S; Cicin I J BUON; 2017; 22(3):586-591. PubMed ID: 28730760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]